Shailesh Bihari

Shailesh Bihari

Auto-generated profile, based on publicly available information

Shailesh Bihari

Department of ICU, Flinders Medical Centre, Adelaide, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2012 in Journal of Clinical Sleep Medicine
Verified
Journal Article
Closed access
SBShailesh Bihari
Shailesh Bihari
RMR Doug McEvoy
R Doug McEvoy
EMElisha Matheson
Elisha Matheson
SKSusan Kim
Susan Kim
RWRichard Woodman
Richard Woodman
ABAndrew D Bersten
Andrew D Bersten
Sleep disturbance is a frequently overlooked complication of intensive care unit (ICU) stay. To evaluate sleep quality among patients admitted to ICU and investigate environmental and non-environmental factors that affect sleep quality in ICU. Over a 22-month period, we consecutively recruited patients who spent ≥ 2 nights post-endotracheal extubation in ICU and who were orientated to time, place, and person on the day of discharge. Self-reported sleep quality, according to a modified Freedman questionnaire, which provided data on self-reported ICU sleep quality in ICU and environmental factors affecting sleep quality in the ICU, were collected. We also investigated non-environmental factors, such as severity of illness, ICU interventions, and medications that can affect sleep quality. Fifty males and 50 females were recruited with a mean (± SD) age of 65.1 ± 15.2 years. APACHE II score at admission to ICU was 18.1 ± 7.5 with duration of stay 6.7 ± 6.5days. Self-reported sleep quality score at home (1 = worst; 10 = best) was 7.0 ± 2.2; this decreased to 4.0 ± 1.7 during their stay in ICU (p < 0.001). In multivariate analysis with APACHE III as severity of illness (R(2) = 0.25), factors [exp(b)(95% CI), p value] which significantly affected sleep in ICU were sex [0.37(0.19-0.72), p < 0.01], age and sex interaction [1.02(1.01-1.03), p < 0.01], bedside phone [0.92(0.87-0.97), p < 0.01], prior quality of sleep at home [1.30(1.05-1.62), p = 0.02], and use of steroids [0.82(0.69-0.98), p = 0.03] during the stay in ICU. Reduced sleep quality is a common problem in ICU with a multifactorial etiology.

1 December 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CHCarol L. Hodgson
Carol L. Hodgson
DCD. James Cooper
D. James Cooper
YAYaseen M Arabi
Yaseen M Arabi
VKVictoria King
Victoria King
ABAndrew Bersten
Andrew Bersten
ANAlistair Nichol
Alistair Nichol
Rationale: Open lung ventilation strategies have been recommended in patients with acute respiratory distress syndrome (ARDS). Objectives: To determine whether a maximal lung recruitment strategy reduces ventilator-free days in patients with ARDS. Methods: A phase II, multicenter randomized controlled trial in adults with moderate to severe ARDS. Patients received maximal lung recruitment, titrated positive end expiratory pressure and further Vt limitation, or control “protective” ventilation. Measurements and Main Results: The primary outcome was ventilator-free days at Day 28. Secondary outcomes included mortality, barotrauma, new use of hypoxemic adjuvant therapies, and ICU and hospital stay. Enrollment halted October 2, 2017, after publication of ART (Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial), when 115 of a planned 340 patients had been randomized (57% male; mean age, 53.6 yr). At 28 days after randomization, there was no difference between the maximal lung recruitment and control ventilation strategies in ventilator-free days (median, 16 d [interquartile range (IQR), 0–21 d], n = 57, vs. 14.5 d [IQR, 0–21.5 d], n = 56; P = 0.95), mortality (24.6% [n = 14/56] vs. 26.8% [n = 15/56]; P = 0.79), or the rate of barotrauma (5.2% [n = 3/57] vs. 10.7% [n = 6/56]; P = 0.32). However, the intervention group showed reduced use of new hypoxemic adjuvant therapies (i.e., inhaled nitric oxide, extracorporeal membrane oxygenation, prone; median change from baseline 0 [IQR, 0–1] vs. 1 [IQR, 0–1]; P = 0.004) and increased rates of new cardiac arrhythmia (n = 17 [29%] vs. n = 7 [13%]; P = 0.03). Conclusions: Compared with control ventilation, maximal lung recruitment did not reduce the duration of ventilation-free days or mortality and was associated with increased cardiovascular adverse events but lower use of hypoxemic adjuvant therapies. Clinical trial registered with www.clinicaltrials.gov (NCT01667146).

1 August 2017 in The Lancet Respiratory Medicine
Verified
Journal Article
Open access
FMFabiana Madotto
Fabiana Madotto
GBGiacomo Bellani
Giacomo Bellani
EFEddy Fan
Eddy Fan
LBLaurent Brochard
Laurent Brochard
PAPravin Amin
Pravin Amin
MVMilic Veljovic
Milic Veljovic
Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non-invasive ventilation. One of the trial's secondary aims was to characterise variations in the demographics, management, and outcome of patients with ARDS. We used the 2016 World Bank countries classification to define three major geo-economic groupings, namely European high-income countries (Europe-High), high-income countries in the rest of the world (rWORLD-High), and middle-income countries (Middle). We compared patient outcomes across these three groupings. LUNG SAFE is registered with ClinicalTrials.gov, number NCT02010073. Of the 2813 patients enrolled in LUNG SAFE who fulfilled ARDS criteria on day 1 or 2, 1521 (54%) were recruited from Europe-High, 746 (27%) from rWORLD-High, and 546 (19%) from Middle countries. We noted significant geographical variations in demographics, risk factors for ARDS, and comorbid diseases. The proportion of patients with severe ARDS or with ratios of the partial pressure of arterial oxygen (PaO2) to the fractional concentration of oxygen in inspired air (FiO2) less than 150 was significantly lower in rWORLD-High countries than in the two other regions. Use of prone positioning and neuromuscular blockade was significantly more common in Europe-High countries than in the other two regions. Adjusted duration of invasive mechanical ventilation and length of stay in the intensive-care unit were significantly shorter in patients in rWORLD-High countries than in Europe-High or Middle countries. High gross national income per person was associated with increased survival in ARDS; hospital survival was significantly lower in Middle countries than in Europe-High or rWORLD-High countries. Important geo-economic differences exist in the severity, clinician recognition, and management of ARDS, and in patients' outcomes. Income per person and outcomes in ARDS are independently associated. European Society of Intensive Care Medicine, St Michael's Hospital, University of Milan-Bicocca.

1 September 2020 in Critical Care and Resuscitation
Verified
Journal Article
Open access
SBShailesh Bihari
Shailesh Bihari
JBJonathan Bannard-Smith
Jonathan Bannard-Smith
RBRinaldo Bellomo
Rinaldo Bellomo
• Albumin is the most abundant and perhaps most important protein in human blood. Research has identified many of albumin’s possible roles in modulating acid-base balance, modifying inflammation, maintaining vascular endothelial integrity, and binding endogenous and exogenous compounds. • Albumin plays a key role in the homeostasis of vascular endothelium, offering protection from inflammation and damage to the glycocalyx. • Albumin binds a diverse range of compounds. It transports, delivers and clears drugs, plus it helps with uptake, storage and disposal of potentially harmful biological products. • The biological effects of albumin in critical illness are incompletely understood, but may enhance its clinical role beyond use as an intravenous fluid. In this article, we summarise the evidence surrounding albumin’s biological and physiological effects beyond its use for plasma volume expansion, and explore potential mechanistic effects of albumin as a disease modifier in patients with critical illness.

21 October 2018 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
JMJohan Mårtensson
Johan Mårtensson
SBShailesh Bihari
Shailesh Bihari
JBJonathan Bannard-Smith
Jonathan Bannard-Smith
NGNeil J. Glassford
Neil J. Glassford
PLPatryck Lloyd-Donald
Patryck Lloyd-Donald
RBRinaldo Bellomo
Rinaldo Bellomo

8 November 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMark Plummer
Mark Plummer
MFMark E. Finnis
Mark E. Finnis
LPLiza K. Phillips
Liza K. Phillips
PKPalash Kar
Palash Kar
SBShailesh Bihari
Shailesh Bihari
ADAdam M. Deane
Adam M. Deane
Stress induced hyperglycemia occurs in critically ill patients who have normal glucose tolerance following resolution of their acute illness. The objective was to evaluate the association between stress induced hyperglycemia and incident diabetes in survivors of critical illness. Retrospective cohort study. All adult patients surviving admission to a public hospital intensive care unit (ICU) in South Australia between 2004 and 2011. Stress induced hyperglycemia was defined as a blood glucose ≥ 11.1 mmol/L (200 mg/dL) within 24 hours of ICU admission. Prevalent diabetes was identified through ICD-10 coding or prior registration with the Australian National Diabetes Service Scheme (NDSS). Incident diabetes was identified as NDSS registration beyond 30 days after hospital discharge until July 2015. The predicted risk of developing diabetes was described as sub-hazard ratios using competing risk regression. Survival was assessed using Cox proportional hazards regression. Stress induced hyperglycemia was identified in 2,883 (17%) of 17,074 patients without diabetes. The incidence of type 2 diabetes following critical illness was 4.8% (821 of 17,074). The risk of diabetes in patients with stress induced hyperglycemia was approximately double that of those without (HR 1.91 (95% CI 1.62, 2.26), p<0.001) and was sustained regardless of age or severity of illness. Stress induced hyperglycemia identifies patients at subsequent risk of incident diabetes.